Equillium, Inc. (EQ)
- Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif., May 07, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.
- Simply Wall St.
We're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example...
- Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., April 03, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee appr
